Psychedelic Stocks and ETFs: 2026 Industry Guide

Interest in psychedelic stocks surged after the FDA granted Breakthrough Therapy designations to psilocybin and MDMA between 2017 and 2020. But investing in this sector requires understanding what these companies actually are: mostly clinical-stage biotechs with no approved products, no revenue, and long runways to market. This guide covers the major public companies, the ETF options, what moves prices, and the risks that are specific to this industry — so you can form an informed view before you do anything else.

Quick answer: what are psychedelic stocks?

Psychedelic stocks are shares in companies developing psilocybin, MDMA, ketamine, LSD analogs, or related compounds as prescription medicines. Almost every publicly traded company in this space is clinical-stage: they are running drug trials, not selling approved products. That means they have no operating revenue, are spending down cash raised through equity markets, and face a decade-long path to FDA approval at minimum. They are high-risk speculative investments, not income-generating businesses. Treat them accordingly.

Major publicly traded psychedelic therapy companies

The following companies are the most commonly discussed in this sector as of mid-2026. Pipeline details and financial positions change frequently — always check SEC filings and company investor relations pages for current information.

All five companies are clinical-stage. None had an approved psychedelic medicine generating product revenue as of this writing. Cash positions and burn rates vary — check each company's most recent quarterly filing before drawing conclusions about runway. Timelines for these programs routinely extend beyond initial projections.

For more on the clinical science behind the compounds these companies are developing, see our guides on psilocybin therapy, ketamine therapy, and MDMA therapy.

Psychedelic ETFs

Two exchange-traded funds have been explicitly marketed as psychedelic sector funds, though the ETF landscape in this space has been unstable since 2021.

PSIL — AdvisorShares Psychedelics ETF

PSIL launched in September 2021 as one of the first US-listed psychedelic-focused ETFs. It tracks companies involved in psychedelic research and development. The fund has undergone restructuring since its launch and has seen significant assets-under-management changes alongside the sector's volatility. Verify the fund's current status, expense ratio, and holdings independently before making any decision.

PSY — Horizons Psychedelic Stock Index ETF

PSY trades on the NEO Exchange in Canada and tracks the North American Psychedelics Index. It was launched in early 2021. Like PSIL, it has experienced significant NAV drawdown as the broader sector corrected from its 2021 highs. Canadian investors or those with access to Canadian markets may encounter it more readily than US investors.

What moves psychedelic stock prices?

Several distinct factors drive price movement in psychedelic stocks, and most of them are binary events rather than gradual operational improvements.

FDA decisions and approval milestones

The FDA's approval of Spravato (esketamine) in 2019 for treatment-resistant depression demonstrated that a psychedelic-adjacent drug could reach the US market. That approval created significant investor interest in the broader category. Each subsequent FDA decision — whether a Complete Response Letter, approval, or new Breakthrough Therapy designation — moves individual stocks and sometimes the whole sector.

Phase 3 trial readouts

Clinical trial results are the single biggest catalyst for individual company stocks. A positive Phase 3 readout can double a stock in a day. A negative result or a missed primary endpoint can cut it in half. COMPASS Pathways' positive Phase 3 data in 2025 drove a significant re-rating of CMPS shares. MindMed's Phase 3 progress for MM120 has similarly been a key stock catalyst.

The MAPS/Lykos MDMA complete response letter — August 2024

The most instructive recent example of how a single regulatory decision hits the whole sector happened in August 2024. The FDA issued a Complete Response Letter to Lykos Therapeutics (formerly MAPS PBC) for its MDMA-assisted therapy for PTSD, declining to approve the treatment and requesting an additional Phase 3 trial. This was a significant setback not just for Lykos, but for the broader psychedelic therapy investment thesis. Other psychedelic stocks fell in the days following the decision as investors reassessed FDA risk across the entire category. The episode illustrated that one company's regulatory failure can become a sector-wide event when investors are extrapolating from limited approved-drug precedents.

DEA scheduling changes

Most psychedelics remain Schedule I under the Controlled Substances Act. A DEA decision to reschedule a compound — or a court ruling affecting scheduling — could dramatically change the commercial landscape. Conversely, any signal of stricter enforcement tends to be negative for the sector. Track these developments at our regulatory calendar.

Cash burn and dilution risk

Clinical-stage companies with no revenue must raise capital to fund operations. They typically do this through equity raises, which dilute existing shareholders. When a company announces a large stock offering — especially at a discount to market price — the stock almost always falls. Monitoring the cash runway of any company you follow is essential; it predicts when dilutive raises are likely.

Macro biotech sentiment

Psychedelic stocks tend to move with broader biotech sentiment. When interest rates rise or investors rotate away from speculative growth stocks, small-cap biotechs including psychedelic companies often sell off together. When biotech is in favor, psychedelic companies benefit from the tide. The sector does not trade in isolation.

Risks specific to this sector

Psychedelic drug development carries all the risks of standard clinical-stage biotech investing, plus several risks that are unique to this category.

Schedule I status limits research funding

Most psychedelics are still Schedule I controlled substances at the federal level. This classification makes it harder and more expensive to conduct research. Companies must obtain DEA Schedule I research licenses, work with approved facilities, and navigate restrictions that do not apply to Schedule II or III drugs. This increases costs and slows timelines compared to developing a conventional drug.

Private funding requirement

Because these compounds are not yet approved medicines, companies cannot generate revenue by selling them. All research must be funded through private capital markets. That means ongoing dependence on investor appetite, which fluctuates with the news cycle, interest rates, and broader risk sentiment.

Long timelines

The average time from drug discovery to FDA approval across all drug categories is 10–15 years, and many drugs fail entirely. Psychedelic drug programs are not dramatically different. Investors who bought in expecting rapid approvals in 2021 have learned this lesson as timelines extended. Phase 3 trials alone typically take 3–5 years to complete enrollment and generate results.

Pre-revenue status of all major players

As of mid-2026, no major publicly traded psychedelic therapy company has an approved product generating meaningful commercial revenue. Every company in this space is funding itself from capital raises against the promise of future approvals. Traditional valuation metrics — P/E ratios, revenue multiples — do not apply here. Investors are effectively buying a probability-weighted option on FDA approval.

FDA rejection risk — the Lykos precedent

The August 2024 Complete Response Letter to Lykos for MDMA-assisted therapy is now the defining example of FDA rejection risk in this space. The FDA's concerns centered on functional unblinding in clinical trials (patients and therapists both knew who received MDMA), questions about the therapy component, and data integrity issues at clinical trial sites. These concerns apply broadly to psychedelic therapy trials — blinding is structurally difficult when the active compound produces obvious subjective effects. Future FDA applications in this space will need to address these issues directly. The Lykos rejection is discussed in more depth in our MDMA therapy guide.

The regulatory calendar matters

For psychedelic stocks, the regulatory calendar is as important as earnings season is for conventional stocks. FDA Prescription Drug User Fee Act (PDUFA) dates, Advisory Committee meetings, DEA scheduling hearing dates, and Phase 3 readout windows are the moments that move prices. Missing these catalysts means missing the most important context for evaluating positions.

The Psychedelic Journal tracks FDA and DEA deadlines relevant to psychedelic medicine programs on our regulatory calendar. This is one of the specific ways we add value for readers following this sector: policy and regulatory tracking that sits alongside clinical and scientific coverage.

You can also find primary source data and trial registrations through our data page and sources directory, which index ClinicalTrials.gov registrations and company SEC filings relevant to the psychedelic therapy space.

The bottom line: psychedelic stocks can offer significant upside if clinical programs succeed, but the sector is pre-revenue, regulatory-event-driven, and structurally similar to other speculative clinical-stage biotech categories. Understand what you are buying before you act. And again — nothing on this page is investment advice.